A CTC study using Apheresis in phase-I trials
Research type
Research Study
Full title
A pilot study of the Circulating Tumour Cells (CTCs) enrichment using apheresis collection, and single cell molecular characterization in cancer patients participating in phase-I trials.
IRAS ID
240336
Contact name
Johann S de Bono
Contact email
Sponsor organisation
The Institute of Cancer Research
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
This is a pilot study to test whether a process called apheresis may be implemented in our phase I Drug Development Unit (DDU) to makes analyses that may guide us in selecting optimal treatment strategies in the future on an individual patient basis.
Apheresis has been extensively and safely utilized to acquire rare bone marrow stem cells from the blood of cancer patients. This process will allow us to isolate and study rare tumour cells in a sample of blood collected from patients. Clinical studies suggest that higher numbers of these cancer cells in blood can predict (prognosis).
This study will be conducted at the Royal Marsden NHS Trust. Patients recruited into this study will already have been selected to participate in a Phase 1 research study. It is anticipated that up to 40 patients with metastatic solid organ tumours will be recruited in the initial pilot phase of this study.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
18/LO/2020
Date of REC Opinion
29 Nov 2018
REC opinion
Favourable Opinion